13.4 C
New York
Thursday, November 30, 2023
HomeBBK-FrontBenralizumab for Chronic Spontaneous Urticaria

Benralizumab, an anti–interleukin-5-receptor antibody, was evaluated in a 24-week study involving 12 patients with chronic spontaneous urticaria. The disease was assessed on the basis of urticaria activity scores. After three monthly injections and 2 months without benralizumab, 5 patients had a complete response and 2 had a partial response.


Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -spot_img
[td_block_1 custom_title="Must Read" limit="4" f_header_font_transform="uppercase" ajax_pagination="next_prev" block_template_id="td_block_template_2" m4f_title_font_family="394" m4f_title_font_weight="700" m6f_title_font_family="394" m6f_title_font_weight="700" sort="modified_date" offset="4" m4f_title_font_size="eyJhbGwiOiIyMCIsImxhbmRzY2FwZSI6IjE4IiwicG9ydHJhaXQiOiIxNiJ9" m4f_title_font_line_height="1.3" category_id="121"]
spot_img